Related Experiment Video
Updated: Apr 29, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Assessing the benefits of natriuretic peptides-guided therapy in chronic heart failure
1Cardiology Office, Rheinfelden, Switzerland. praxis@cocco.ch.
Insights
Natriuretic peptides (NPs) may help guide heart failure (HF) treatment, especially for patients with preserved ejection fraction. However, more research is needed to confirm effectiveness across different settings and patient groups.
Area of Science:
- Cardiology
- Biomarkers
Background:
- Heart failure (HF) poses a significant public health challenge, particularly in aging populations.
- Optimizing HF management remains complex despite therapeutic advancements.
- Natriuretic peptides (NPs) correlate with cardiac morbidity and mortality, suggesting their potential in guiding HF treatment.
Purpose of the Study:
- To evaluate the utility of natriuretic peptides (NPs) in guiding the management of chronic heart failure (HF).
- To address uncertainties regarding NP-guided therapy in diverse clinical settings and patient demographics.
Main Methods:
- Analysis of existing data on NP-guided therapy in chronic HF.
- Focus on studies involving patients with preserved left ventricular function.
- Acknowledging limitations in sample size, assay variability, and protocol differences.
Main Results:
- Available data suggest NP-guided therapy is a reasonable consideration for HF with preserved systolic function.
- Significant limitations exist, including insufficient patient numbers for definitive conclusions and variability in study methodologies.
- Unanswered questions remain regarding optimal NP selection, threshold levels, and applicability across different patient subgroups.
Conclusions:
- While promising for HF with preserved ejection fraction, NP-guided therapy requires further investigation.
- Clinical acceptance hinges on demonstrating clear therapeutic consequences and consistent results across various healthcare settings.
- Ongoing multicenter studies aim to resolve remaining clinical questions regarding NP-guided HF management.
Abstract:
Heart failure (HF) is a major public heart burden among the ageing population. Optimizing management of patients remains challenging despite many advances in therapy for this pathology. Natriuretic peptides (NPs) are related to cardiac morbidity and mortality and their use in guiding treatment might help. Most data on the value of NPs-guided therapy in chronic HF came from centers with high experience in the therapy of HF. Ninety percent of patients had preserved left ventricular function. The story is just too complex to have the final answer. The numbers of treated patients is insufficient to allow a final decision. Most data derive from centers with high skills and were obtained with different assays, different protocols. Many questions are open. Can similar results be obtained in less specialized centers? It is undecided which NP should be used and how high should be the levels to guide the therapy. Which patients might especially benefit from this approach? Is the approach useful in patients with reduced systolic function? Is the strategy as useful in the elderly as in younger patients? In spite of these limitations, available data suggest that it is reasonable to consider the use of NPs to guide the therapy of HF with preserved systolic function. In order to answer some of the questions, a multicenter, prospective study began in January 2013. However, NP guided therapy in chronic HF will only find acceptance in clinical practice if its use results in therapeutic consequences.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure V: Medical Management
01:22Heart Failure VI: Adjunct Therapies
01:22Heart Failure Drugs: Diuretics
01:29Heart Failure II: Pathophysiology
01:30Heart Failure VII: Nursing Interventions